CORRECTION: Organon & Co. Revises FY24 Revenue Guidance From $6.2B-$6.5B To $6.25-$6.45B Vs $6.407B Est.
Portfolio Pulse from Benzinga Newsdesk
Organon & Co. has revised its FY24 revenue guidance from $6.2B-$6.5B to $6.25B-$6.45B, compared to the $6.407B estimate. Other financial metrics remain unchanged except for R&D expenses, which have been adjusted to $430M-$530M.
August 06, 2024 | 4:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Organon & Co. has revised its FY24 revenue guidance slightly upwards to $6.25B-$6.45B from $6.2B-$6.5B, aligning closely with the $6.407B estimate. R&D expenses have also been adjusted to $430M-$530M.
The slight upward revision in revenue guidance and the adjustment in R&D expenses indicate a positive outlook for Organon & Co. This could lead to a short-term positive impact on the stock price as it aligns closely with market estimates.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100